The aim of this Research Training Program is to prepare highly-qualified physicians for an academic research career in medical or gynecologic oncology by developing research skills in cancer biology and cancer therapy. The general areas of research training include: (1) Clinical Transplantation for Malignant Disease; (2) Tumor Immunology; (3) Transplantation Biology; (4) Human Immunogenetics; (5) Normal and Malignant Hematopoiesis; (6) Gynecologic Oncology; (7) Genitourinary Cancer; (8) Breast Cancer; and (9) Molecular Medicine. All trainees will be members of the Medical Oncology or Gynecologic Oncology Fellowship Programs of the University of Washington and the Fred Hutchinson Cancer Research Center. Funds are requested for the research training years only - four positions for the second year and four positions for the third year of the Medical Oncology Fellowship Program and one position for the first year and one position for the second year of the Gynecologic Oncology Fellowship Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA009515-21
Application #
6948970
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
1985-07-01
Project End
2010-06-30
Budget Start
2005-08-05
Budget End
2006-06-30
Support Year
21
Fiscal Year
2005
Total Cost
$491,292
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Baker, Kathryn T; Salk, Jesse J; Brentnall, Teresa A et al. (2018) Precancer in ulcerative colitis: the role of the field effect and its clinical implications. Carcinogenesis 39:11-20
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467
Dossa, Robson G; Cunningham, Tanya; Sommermeyer, Daniel et al. (2018) Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood 131:108-120
Vandeven, Natalie; Lewis, Christopher W; Makarov, Vladimir et al. (2018) Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. Clin Cancer Res 24:963-971
Paulson, Kelly G; Park, Song Youn; Vandeven, Natalie A et al. (2018) Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 78:457-463.e2
Chow, Victor A; Shadman, Mazyar; Gopal, Ajay K (2018) Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood 132:777-781
Salk, Jesse J; Schmitt, Michael W; Loeb, Lawrence A (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269-285
Veatch, Joshua R; Lee, Sylvia M; Fitzgibbon, Matthew et al. (2018) Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest 128:1563-1568
Greenbaum, Adam M; Green, Damian J; Holmberg, Leona A et al. (2018) Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Res 53:223-226

Showing the most recent 10 out of 243 publications